Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
|Videos|July 5, 2021
Pharmacist Medication Insights: for Panzyga for Primary Humoral Immunodeficiency
Author(s)Saro Arakelians, PharmD
Panzyga is indicated for the treatment of primary humoral immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and chronic immune thrombocytopenia.
Advertisement
Panzyga (immune globulin intravenous [Human]-ifas) is indicated for the following:
- For the treatment of adults 18 years of age and older with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment.
- Primary humoral immunodeficiency (PI) in patients 2 years of age and older.
- Chronic immune thrombocytopenia (ITP) in adults.
Advertisement
Related to this article
This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Public data may help identify drugs associated with shortages, but hospital inventory and purchasing data could make early-warning tools more useful.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Ali A. Habib, MD, discusses how NIMBLE’s hospitalization findings complement symptom outcomes for investigational cemdisiran and highlights pharmacists’ role in vaccination tracking and infection-risk counseling.
Advertisement
Advertisement